Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome
العنوان: | Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome |
---|---|
المؤلفون: | Vittorio Martinelli, Carolyn A Young, Adriana Carra, Catherine Lubetzki, Maria A. Rocca, John King, Kjell-Morten Myhr, Mads Ravnborg, Mariaemma Rodegher, Sámuel Komoly, Paolo Preziosa, Hans-Peter Hartung, Xavier Montalban, Lucia Moiola, Jan Hillert, Peter Rieckmann, Irina Elovaara, Letizia Leocani, Giancarlo Comi, Ovidiu Bajenaru, Franz Fazekas, Massimo Filippi, Daniel Wynn |
المساهمون: | Comi, Giancarlo, Martinelli, V, Rodegher, M, Moiola, L, Leocani, ANNUNZIATA MARIA LETIZIA, Bajenaru, O, Carra, A, Elovaara, I, Fazekas, F, Hartung, Hp, Hillert, J, King, J, Komoly, S, Lubetzki, C, Montalban, X, Myhr, Km, Preziosa, P, Ravnborg, M, Rieckmann, P, Rocca, Ma, Wynn, D, Young, C, Filippi, Massimo |
المصدر: | Comi, G, Martinelli, V, Rodegher, M, Moiola, L, Leocani, L, Bajenaru, O, Carra, A, Elovaara, I, Fazekas, F, Hartung, H P, Hillert, J, King, J, Komoly, S, Lubetzki, C, Montalban, X, Myhr, K M, Preziosa, P, Ravnborg, M, Rieckmann, P, Rocca, M A, Wynn, D, Young, C & Filippi, M 2013, ' Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome ', Multiple sclerosis, vol. 19, no. 8, pp. 1074-1083 . https://doi.org/10.1177/1352458512469695Test |
بيانات النشر: | SAGE Publications, 2012. |
سنة النشر: | 2012 |
مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Pathology, Multiple Sclerosis, Placebo, Gastroenterology, Lesion, Atrophy, Double-Blind Method, Medizinische Fakultät, Internal medicine, medicine, Humans, ddc:610, Glatiramer acetate, Adverse effect, Clinically isolated syndrome, business.industry, Multiple sclerosis, Hazard ratio, Brain, Glatiramer Acetate, medicine.disease, Magnetic Resonance Imaging, Clinically definite multiple sclerosis glatiramer acetate clinically isolated syndrome (CIS) brain atrophy MRI relapse EDSS RELAPSING MULTIPLE-SCLEROSIS NEUROLOGIC IMPAIRMENT DISEASE-ACTIVITY DOUBLE-BLIND DISABILITY MULTICENTER PREDICTORS TRIAL, Neurology, Disease Progression, Female, Neurology (clinical), medicine.symptom, Peptides, business, Immunosuppressive Agents, Demyelinating Diseases, medicine.drug |
الوصف: | Background: The placebo-controlled phase of the PreCISe study showed that glatiramer acetate delayed onset of clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndrome and brain lesions on MRI. Objective: To compare the effects of early versus delayed glatiramer acetate treatment in the open-label phase of PreCISe. Methods: Patients with a clinically isolated syndrome suggestive of MS with unifocal manifestation and ≥2 T2-weighted brain lesions were randomized to receive glatiramer acetate 20 mg/d (early-treatment, n=198) or placebo (delayed-treatment, n=211) for 36 months or until conversion to CDMS, followed by open-label glatiramer acetate treatment for two years. Results: Early glatiramer acetate treatment reduced CDMS conversion risk by 41% (hazard ratio 0.59, 95% confidence interval 0.44–0.80; p=0.0005) versus delayed-treatment, and was associated with a 972-day delay (185%) in conversion to CDMS, less brain atrophy (−28%, p=0.0209), fewer new T2 lesions/year (−42%, Conclusions: Effects of early glatiramer acetate treatment on the rate of conversion to CDMS and on MRI measures of disease activity and lesion burden support initiating glatiramer acetate treatment soon after the first clinical symptoms suggestive of MS and continuing treatment to sustain benefits. |
وصف الملف: | application/pdf |
تدمد: | 1477-0970 1352-4585 |
الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c01bed1e3bb2b78177be853262f6120Test https://doi.org/10.1177/1352458512469695Test |
حقوق: | OPEN |
رقم الانضمام: | edsair.doi.dedup.....0c01bed1e3bb2b78177be853262f6120 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 14770970 13524585 |
---|